Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation
- PMID: 30116017
- DOI: 10.1038/s41409-018-0291-5
Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation
Comment in
-
Treatment of relapsed aggressive adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide.Bone Marrow Transplant. 2021 Nov;56(11):2862-2863. doi: 10.1038/s41409-021-01432-5. Epub 2021 Aug 12. Bone Marrow Transplant. 2021. PMID: 34385616 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources